Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine)

N/A

Report date: 2024/01/03 20:01:34

Base Information

Drug NameAutologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine)
Drug Alias NameE-SYNC T Cells therapy(California Institute For Regenerative Medicine)Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR T Cells therapy(California Institute For Regenerative Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-EGFRvIIIAnti-Ephrin type-A receptor 2
TargetsEpidermal growth factor receptor variant IIIEphrin type-A receptor 2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCalifornia Institute For Regenerative MedicineNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesCalifornia Institute For Regenerative MedicineNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A